The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review Blythe AdamsonDobromir DimitrovRuanne Barnabas Systematic Review Open access 30 January 2017 Pages: 1 - 12
Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey Jeff RichardsonAngelo IezziAimee Maxwell Original Research Article Open access 04 November 2016 Pages: 13 - 23
Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK Jameel NazirMalin BerlingAdrian Wagg Original Research Article Open access 30 January 2017 Pages: 25 - 36
Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model Barbara de GraaffLei SiAndrew J. Palmer Original Research Article Open access 16 November 2016 Pages: 37 - 51
A Single-Center Cost Analysis of Treating Primary and Metastatic Brain Cancers with Either Brain Laser Interstitial Thermal Therapy (LITT) or Craniotomy Eric C. LeuthardtJeff VoigtPete Sylvester Original Research Article Open access 03 November 2016 Pages: 53 - 63
Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review Ilke AkpinarPhilip JacobsTien Dat Tran Short Communication Open access 08 November 2016 Pages: 65 - 68
Comment on: “Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review” Przemysław Holko Letter to the Editor Open access 27 January 2017 Pages: 69 - 70
Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review” Ilke AkpinarPhilip JacobsDat T. Tran Letter to the Editor Open access 27 January 2017 Pages: 71 - 71